Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: A randomized, placebo-controlled, natural exposure, clinical trial

Allergy and Asthma Proceedings

Volumn 34, Issue 3, 2013, Pages 247-254

  Carr, Warner W ^a   Nayak, Anjuli S ^b   Ratner, Paul H ^c   Gow, James A ^d   McNamara, Timothy R ^d   Williams, Jon I ^d  

^a Allergy & Asthma Associates of Southern California   (United States)

^b Sneeze Wheeze and Itch Associates   (United States)

^c Sylvana Research   (United States)

^d ISTA Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEPOTASTINE; EYE DROPS; PLACEBO;

ADOLESCENT; ADULT; CLINICAL ASSESSMENT; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INSTILLATION SITE PAIN; MALE; MULTICENTER STUDY; NAUSEA; NOSE EDEMA; OCULAR PRURITUS; OUTCOME ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINORRHEA; SEASONAL ALLERGIC CONJUNCTIVITIS; SIDE EFFECT; TASTE; TREATMENT DURATION; UPPER RESPIRATORY TRACT CONGESTION; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-ALLERGIC AGENTS; CHILD; CONJUNCTIVITIS, ALLERGIC; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PIPERIDINES; PYRIDINES; SEASONS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878268835     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2013.34.3671     Document Type: Conference Paper

References (36)

1. Bielory L. Allergic and immunologic disorders of the eye. Part II: Ocular allergy. J Allergy Clin Immunol 106: 1019-1032, 2000.
2. Settipane RA. Demographics and epidemiology of allergic and nonallergic rhinitis. Allergy Asthma Proc 22: 185-189, 2001.
3. Butrus S, and Portela R. Ocular allergy: Diagnosis and treatment. Ophthalmol Clin North Am 18: 485-492, 2005.
4. Chigbu DI. The management of allergic eye diseases in primary eye care. Cont Lens Anterior Eye 32: 260-272, 2009.
5. Bielory L. Allergic conjunctivitis and the impact of allergic rhinitis. Curr Allergy Asthma Rep 10: 122-134, 2010.
6. Singh K, Axelrod S, and Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988-1994. J Allergy Clin Immunol 126: 778-783, 2010.
7. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: Complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 81: 478-518, 1998.
8. Raizman MB. Results of a survey of patients with ocular allergy treated with topical ketorolac tromethamine. Clin Ther 17: 882-890, 1995.
9. Berger W, Abelson MB, Gomes PJ, et al. Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy. Ann Allergy Asthma Immunol 95: 361-371, 2005.
10. Kari O, and Saari KM. Updates in the treatment of ocular allergies. J Asthma Allergy 3: 149-158, 2010.
11. Leonardi A. Role of histamine in allergic conjunctivitis. Acta Ophthalmol Scand Suppl 78: 18-21, 2000.
12. Calder VL, and Lackie PM. Basic science and pathophysiology of ocular allergy. Curr Allergy Asthma Rep 4: 326-331, 2004.
13. Abelson MB, Smith L, and Chapin M. Ocular allergic disease: Mechanisms, disease sub-types, treatment. Ocul Surf 1: 127-149, 2003.
14. Simons FE, and Simons KJ. The pharmacology and use of H1-receptor- antagonist drugs. N Engl J Med 330: 1663-1670, 1994.
15. Simons FE. Advances in H1-antihistamines. N Engl J Med 21: 2203-2217, 2004.
16. Bielory L. Allergic conjunctivitis: The evolution of therapeutic options. Allergy Asthma Proc 33: 129-139, 2012.
17. Williams J, Gow J, and Klier S. Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate. Curr Med Res Opin 26: 2329-2338, 2010.
18. Kida T, Fujii A, Sakai O, et al. Bepotastine besilate, a highly selective histamine H1 receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models. Exp Eye Res 91: 85-91, 2010.
19. Lyseng-Williamson KA. Oral bepotastine: In allergic disorders. Drugs 70: 1579-1591, 2010.
20. Ueno M, Inagaki N, Nagai H, and Koda A. Antiallergic action of betotastine besilate (TAU-284) in animal models: a comparison with ketotifen. Pharmacology 57: 206-214, 1998.
21. Murata T, Matsumoto Y, Suzuki T, et al. Effect of betotastine besilate (TAU-284), a novel anti-allergic agent, on experimental allergic rhinitis. Arerugi 46: 576-584, 1997.
22. Baba S, Takasaki T, Baba K, et al. Late phase II clinical study of TAU-284 for perennial allergic rhinitis - Dose finding study by the double-blind method [in Japanese]. J Clin Ther Med 13: 1259-1286, 1997.
23. Baba S, Takasaka T, Baba K, et al. Long-term treatment of TAU-284 (betotastine besilate) on perennial allergic rhinitis [in Japanese]. J Clin Ther Med 13: 1361-1382, 1997.
24. Ishibashi Y, Harada S, Niimura M, et al. Late phase II study of TAU-284 (betotastine besialte) on chronic urticaria - Optimal dose finding study by double-blind technique [in Japanese]. J Clin Ther Med 13: 1237-1257, 1997.
25. Yato N, Murata T, Saito N, et al. Anti-allergic activity of betotastine besilate (TAU284), a new anti-allergic drug (TNB-HO- 01). Folia Pharmacol Jpn 110: 19-29, 1997.
26. Mitsubishi Tanabe Pharma Corp. (formerly Tanabe Seiyaku Co., Ltd.). Talion package insert. Osaka, Japan; October 2009.
27. Abelson MB, Torkildsen GL, Williams JI, et al. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: A phase III, single-center, prospective, randomized, doublemasked, placebo-controlled, conjunctival allergen challenge assessment in adults and children. Clin Ther 31: 1908-1921, 2009.
28. Macejko TT, Bergmann MT, Williams JI, et al. Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis. Am J Ophthalmol 150: 122-127, 2010.
29. Meier EJ, Torkildsen GL, Gow JA, et al. Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis. Allergy Asthma Proc 33: 265-274, 2012.
30. Abelson M, Chambers W, and Smith L. Conjunctival allergen challenge: A clinical approach to studying allergic conjunctivitis. Arch Opthalmol 108: 84-88, 1990.
31. Abelson MB, and Loeffler O. Conjuctival allergen challenge: Models in the investigation of ocular allergy. Curr Allergy Asthma Rep 3: 363-368, 2003.
32. Abelson M, Howes J, and George M. The conjunctival provocation test model of ocular allergy: Utility for assessment of an ocular corticosteroid, loteprednol etabonate. J Ocul Pharmacol Ther 14: 533-542, 1998.
33. Abelson MB, and Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am J Ophthalmol 125: 797-804, 1998.
34. Juniper EF, Thompson AK, Ferrie PJ, and Roberts JN. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol 104: 364-369, 1999.
35. Enomoto T, Lu H, Yin M, et al. Evaluation of the efficacy and safety of olopatadine and fexofenadine compared with placebo in Japanese cedar pollinosis using an environmental exposure unit. J. Investig Allergol Clin Immunol 19: 299-305, 2009.
36. Whitcup S, Bradford R, Lue J, et al. Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis. Clin Ther 26: 29-34, 2004.